StocksMediumUpdated•Originally published 3 November 2026•Updated 3 November 2026•
1 min read
Precision BioSciences Beats Q3 Estimates with -$0.28 GAAP EPS
Key Facts
1Precision BioSciences reported financial results for the third quarter ended September 30, 2026.
2The company continues to advance its ARCUS platform for in vivo gene editing therapies for high unmet need diseases.
Precision BioSciences reported a GAAP EPS of -$0.28 for the third quarter ended September 30, 2026. This result beat analyst estimates by $0.57, according to a company statement released via Business Wire.
DTIL closed at $6.95 on November 2, 2026, with the stock trading between a session low of $6.82 and a high of $7.42. The company continues to advance its proprietary ARCUS platform for in vivo gene editing therapies targeting diseases with high unmet medical needs.